Prescriptions for ivermectin

PSA is aware that some pharmacists have experienced an increase in presentations of prescriptions for ivermectin, including where the patient is unwilling or unable to discuss what they are being used for.  The approved indications in Australia for ivermectin are for the treatment of roundworm infections, scabies and inflammatory rosacea. The use of ivermectin for the treatment of COVID-19 has not been proven. The Cochrane Review published on 28 July 2021 included that:  There is uncertainty about the efficacy and safety of ivermectin used to treat or prevent COVID-19, although the evidence base is limited. Evaluation is continuing in 31 ongoing studies. At this time there is no evidence to support the use of ivermectin for treating or preventing COVID-19 infection. Current Australian advice includes the following: The National COVID-19 Clinical Evidence Taskforce has issued a high priority recommendation: Do not use ivermectin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.  Advice has also been issued by the TGA that ivermectin has not been approved in Australia (or other OECD countries) to prevent or treat COVID-19 disease, and should not be imported for this indication. Some doctors may decide to prescribe ivermectin for off-label use taking into account potential risks and benefits and with appropriate informed consent. However, given the lack of evidence to support use of ivermectin for COVID-19, it would be difficult for a pharmacist to professionally justify off-label supply of ivermectin outside of a well-designed clinical trial. Therefore, PSA recommends that pharmacists do not supply ivermectin for the treatment or prevention of COVID-19. Should pharmacists be unable to establish intended use of an ivermectin prescription, supply should be declined. As a Member of PSA, we are here to support you. If you identify unusual requests for ivermectin, please make contact so that we can pass your concerns to regulatory authorities: send an email to policy@psa.org.au, or  call 1300 369 772, the Pharmacist to Pharmacist Advice Line exclusive to PSA Members.